Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Metastatic melanoma presenting with subacute sensory neuronopathy

    Research output: Contribution to journalLetterResearchpeer-review

  2. Quantitative electromyography: Normative data in paraspinal muscles

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Conference report on contractures in musculoskeletal and neurological conditions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Molecular indicators of denervation in aging human skeletal muscle

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Moderate-intensity aerobic exercise improves physical fitness in bethlem myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quantitative Muscle MRI and Clinical Findings in Women With Pathogenic Dystrophin Gene Variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Myopathy can be a key phenotype of membrin (GOSR2) deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cardiac Involvement in Women With Pathogenic Dystrophin Gene Variants

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Srikanth Muppidi
  • Kimiaki Utsugisawa
  • Michael Benatar
  • Hiroyuki Murai
  • Richard J Barohn
  • Isabel Illa
  • Saiju Jacob
  • John Vissing
  • Ted M Burns
  • John T Kissel
  • Richard J Nowak
  • Henning Andersen
  • Carlos Casasnovas
  • Jan L de Bleecker
  • Tuan H Vu
  • Renato Mantegazza
  • Fanny L O'Brien
  • Jing Jing Wang
  • Kenji P Fujita
  • James F Howard
  • REGAIN Study Group
View graph of relations

Introduction: Eculizumab is effective and well tolerated in patients with antiacetylcholine receptor antibody-positive refractory generalized myasthenia gravis (gMG; REGAIN; NCT01997229). We report an interim analysis of an open-label extension of REGAIN, evaluating eculizumab's long-term safety and efficacy. Methods: Eculizumab (1,200 mg every 2 weeks for 22.7 months [median]) was administered to 117 patients. Results: The safety profile of eculizumab was consistent with REGAIN; no cases of meningococcal infection were reported during the interim analysis period. Myasthenia gravis exacerbation rate was reduced by 75% from the year before REGAIN (P < 0.0001). Improvements with eculizumab in activities of daily living, muscle strength, functional ability, and quality of life in REGAIN were maintained through 3 years; 56% of patients achieved minimal manifestations or pharmacological remission. Patients who had received placebo during REGAIN experienced rapid and sustained improvements during open-label eculizumab (P < 0.0001). Discussion: These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.

Original languageEnglish
JournalMuscle & Nerve
Volume60
Issue number1
Pages (from-to)14-24
Number of pages11
ISSN0148-639X
DOIs
Publication statusPublished - 1 Jul 2019

    Research areas

  • MG-ADL, MG-QOL15, MGC, QMG, eculizumab, myasthenia gravis

ID: 58110164